|
|
|
|
IntelGenx Receives FDA Complete Response Letter CPI-300
IntelGenx announced receipt of a Complete Response Letter from the U.S.Food and Drug Administration ("FDA") regarding the Company's New Drug Application ("NDA") for its antidepressant CPI-300, which it developed with Cary Pharmaceuticals ("Cary Pharma")...
|
|
|
Insulin study could lead to new dosage devices
Buy Maxalt Without a Prescription Buy no Prescription Strattera Order Tamiflu no Prescription Online Buy Medrol Without a Prescription Buy Naltrexone Without a Prescription Buy no Prescription Antabuse Online Buy Boniva no Prescription Buy Propecia Without a...
|
|
|
IntelGenxs Generic Wellbutrin XL Delayed by Complete Response Letter
The FDAs complete response letter for IntelGenxs generic version of Wellbutrin IntelGenxs Generic Wellbutrin XL Delayed by Complete Response Letter.
|
|
|
IntelGenx obtains FDA complete response letter for depression drug
(Datamonitor via COMTEX) IntelGenx, a drug delivery company, has received a complete response letter from the FDA regarding the company's new drug application, or NDA, for its antidepressant CPI-300, which it developed with Cary Pharmaceuticals.According to...
|
|
|
New Study: Paxil Neutralizes Breast Cancer Drug Tamoxefin
A new study has determined the antidepressant Paxil, taken while being treated for estrogen sensitive breast cancer with Tamoxefin, increased the risk of death by blocking the beneficial effects of Tamoxefin.The study conducted by the (ICES) in Toronto, and...
|
|
|
Paxil blocks effect of breast cancer drug
More on Research Getting too old, too fast...Researchers studying... TV can cut your life short... Can cellphones boost... Allergy epidemic may start... Most Read Williams aide lashes out... A popular antidepressant eradicates the benefits of life...
|
|
|
Paxil blocks effect of breast cancer drug
A popular antidepressant eradicates the benefits of life-saving breast cancer drug tamoxifen, a new Ontario study shows.The study of 2,430 women taking tamoxifen showed the drug's potent cancer-fighting capacity was lost in patients using paroxetine anti...
|
|
|
FDA Asks IntelGenx to Fine-Tune CMO and Food Effect Details for Antidepressant Approval
IntelGenxreceived a complete response letter from the FDA regarding the NDA for its antidepressant CPI-300.The agency raised two issues: the qualification of a commercial manufacturing site and the food effect, which was observed both in CPI-300 and the...
|
|
|
IntelGenx Receives FDA Complete Response Letter CPI-300
IntelGenx Corp.(TSX VENTURE: IGX)(OTCBB: IGXT) ('IntelGenx') today announced receipt of a Complete Response Letter from the U.S. Food and Drug Administration ('FDA') regarding the Company's New Drug Application ('NDA') for its antidepressant CPI-300, which...
|
|
|
An Unusual Side Effect
Dr Boyd is staff psychiatrist at the Cambridge Health Alliance, assistant clinical professor of psychiatry at Harvard Medical School, and associate director of Physician Health Services/Mass Medical Society in Boston.He reports no conflicts of interest...
|
|
|
Firm halts antidepressant research
A major pharmaceutical firm is halting research into antidepressants in a bid to save 500m a year in costs by 2012.GlaxoSmithKline announced the move as it unveiled an 18% rise in full-year pre-tax profits to 7.9bn. This was an increase of 16% to 28.4bn in...
|
|
|
GlaxoSmithKline to refocus some research and seek efficiencies, despite posting huge 4th-qtr 2009 profits rise
February 2010 3 February 2010 3 February 2010 Recent Articles 5 February 2010 5 February 2010 5 February 2010 Related Discussion There are no related discussions.Latest Comments There are no comments for this article Article | 5 February 2010 Although not...
|
|
|
Efficacy Called into Question
Hugely Profitable Market Could Be Decimated If These Drugs Only Benefit Severely Depressed Patricia F.Dimond, Ph. click to enlarge Some studies have shown that more than half the people who take antidepressants never get relief. (Fotolia) Antidepressants...
|
|
|
Antidepressant Efficacy Called into Question
Hugely Profitable Market Could Be Decimated If These Drugs Only Benefit Severely Depressed Patricia F.Dimond, Ph. click to enlarge Some studies have shown that more than half the people who take antidepressants never get relief. (Fotolia) Antidepressants...
|
|
|
Biovail Comments on Proposed Generic Wellbutrin XL Trial
- BiovailCorporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched...
|
|
|
Biovail Comments on Proposed Generic Wellbutrin XL Trial
- Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched...
|
|
|
Will generic Wellbutrin live up to brand?
Free newsletter via e-mail Related Stories Tools It's not often that we get data on patients switching from a branded med to a rival generic.But complaints about Teva Pharmaceutical Industries' version of the antidepressant Wellbutrin XL drove FDA to...
|
|
|
BiomedReports: News and FDA Updates for Access (OTC:ACCP), Biovail (NYSE:BVF), Columbia (Nasdaq:CBRX)
BiomedReports: News and FDA Updates for Access (OTC:), Biovail (NYSE:), Columbia (Nasdaq:) Monday January 5, 010 04:33:05 EST Pasadena, CA, Jan 5, 010 (M PRESSWIRE via COMTEX News Network) -- BioMedReports.Com, the news portal which covers Wall Street's...
|
|
|
Biovail Comments On Proposed Generic Wellbutrin XL(R) Trial
Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched...
|
|
|
Biovail Comments On Proposed Generic Wellbutrin XL(R) Trial
Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.According to Teva, the trial is intended to address reports of inefficacy and adverse events by consumers who switched...
|
|
|
Will generic Wellbutrin live up to brand?
It's not often that we get data on patients switching from a branded med to a rival generic.But complaints about Teva Pharmaceutical Industries' version of the antidepressant Wellbutrin XL drove FDA to study the matter. The generics giant promised...
|
|
|
Biovail Corporation (BVF) Comments on Proposed Generic Wellbutrin XL(R) Trial
TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.Biovail Corporation (BVF) Comments on Proposed Generic Wellbutrin XL(R) Trial.
|
|
|
IntelGenx to receive US patent for bupropion HCl
IntelGenx Corp.announced that the US Patent and Trademark Office (USPTO) has issued a formal Notice of Allowance for a key patent application protecting IntelGenx's CPI-300, a novel, high strength formulation of bupropion hydrochloride (HCl), the active...
|
|
|
Medical News: Biovail Comments On Proposed Generic Wellbutrin XL(R) Trial
Biovail Corporation (NYSE/TSX: BVF) today commented on a proposed clinical trial recently announced by Teva Pharmaceutical Industries Ltd.Medical News: Biovail Comments On Proposed Generic Wellbutrin XL(R) Trial.
|
|
|
Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial
_ Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial.
|
